February 20, 2026 – Masimo Corporation today announced that it has entered into a definitive agreement to be acquired by Danaher Corporation for $9.9 billion.
The transaction was unanimously approved by both Masimo’s Board of Directors and Danaher’s Board of Directors.
Masimo will become a standalone business unit and brand within Danaher’s Diagnostics segment and will operate autonomously while strengthening Danaher’s offering in acute care settings.
The transaction is expected to close in the second half of 2026. Masimo will report its fourth quarter and full-year 2025 results on February 26. Due to the Transaction, Masimo will not be hosting an earnings conference call.